Tag Archive for: abiraterone acetate

ARTO Trial Final Results: Long-Term Survival Benefit of SBRT Added to Abiraterone in Oligometastatic mCRPC

The phase 2 ARTO trial findings, published on The Lancet, provides stronger evidence that metastasis-directed SBRT can improve outcomes in oligometastatic castration-resistant prostate cancer. In this randomized study, 157 patients were enrolled across 16 academic and community centers in Italy and assigned 1:1 to abiraterone plus ADT with or without SBRT to all visible metastatic […]

Darolutamide Versus Abiraterone-Based Triplets in mHSPC: Real-World Signals from the ARON-3 Study

Using data from the international ARON-3 real-world study, investigators performed a retrospective head-to-head comparison of darolutamide- and abiraterone-based triplet therapy in patients with metastatic hormone-sensitive prostate cancer. The comparison included 247 patients treated with darolutamide plus docetaxel plus androgen deprivation therapy or abiraterone plus docetaxel plus androgen deprivation therapy across 37 institutions in 14 countries. […]

Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC

A large international Phase 3 clinical trial  is evaluating a new treatment combination for men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet undergone chemotherapy (in castration resistant settings, prior chemo is allowed). The study is testing xaluritamig (AMG 509) together with abiraterone acetate against the investigator’s choice of standard therapies (docetaxel, cabazitaxel, […]

AMPLITUDE: a Phase 3 Clinical Trial of Niraparib Combined with Abiraterone Acetate for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer

Another Trial Supports Low-Dose Abiraterone Acetate in mCRPC

This study, published in JCO Global Oncology and focused on abiraterone acetate (AA), a drug used to treat metastatic castration-resistant prostate cancer, suggests that a smaller dose of AA is as effective as the standard dose (we already talked about another study pointing in the same direction in Singapore, but this sample is bigger). The […]